Breast Cancer: No Chemotherapy or Radiation
Breast Cancer Treatments Without Chemotherapy or Radiation
Patients may opt out of chemo/radiation due to age, stage of cancer, type of tumor, previous toxicities, genetic predispositions, or personal beliefs. In such cases, targeted therapy, hormone therapy, immunotherapy, and surgical options often take center stage.
1. Hormone (Endocrine) Therapy
Used for: Hormone-receptor-positive (ER+/PR+) breast cancers.
Main Medications:
-
Tamoxifen – blocks estrogen receptors (SERM).
-
Aromatase Inhibitors (AIs):
-
Anastrozole, Letrozole, Exemestane – reduce estrogen production in postmenopausal women.
-
-
Fulvestrant (Faslodex) – estrogen receptor degrader (SERD), injection form.
Immediate Side Effects:
-
Hot flashes, mood swings, fatigue
-
Vaginal dryness, decreased libido
-
Bone/joint pain (especially AIs)
Long-Term Effects:
-
Increased risk of blood clots (Tamoxifen)
-
Bone thinning/osteoporosis (AIs)
-
Liver enzyme elevations
-
Cognitive changes (“chemo brain” effect, even without chemo)
2. Targeted Therapy
Used for: HER2-positive cancers or cancers with specific mutations.
Main Medications:
-
Trastuzumab (Herceptin)
-
Pertuzumab (Perjeta)
-
Neratinib, Lapatinib (oral HER2 inhibitors)
-
CDK4/6 inhibitors: Palbociclib (Ibrance), Ribociclib, Abemaciclib
Immediate Side Effects:
-
Diarrhea (especially Neratinib, Abemaciclib)
-
Neutropenia (low white blood cells)
-
Heart toxicity (Herceptin requires cardiac monitoring)
-
Nausea, fatigue
Long-Term Effects:
-
Cardiac dysfunction (Herceptin)
-
Kidney and liver function changes (CDK4/6 inhibitors)
-
Possible chronic fatigue
3. Immunotherapy
Used in: Triple-negative breast cancer (TNBC), usually in combination with checkpoint inhibitors.
Main Drugs:
-
Atezolizumab, Pembrolizumab (Keytruda)
Immediate Side Effects:
-
Flu-like symptoms
-
Skin rash
-
Inflammation of organs (autoimmune responses)
-
Pneumonitis, colitis, hepatitis, endocrinopathies
-
Long-Term Effects:
-
Possible long-term organ inflammation
-
Adrenal or thyroid dysfunction
4. Injections: Faslodex & Others
-
Fulvestrant (Faslodex) is administered intramuscularly into the gluteal muscle, usually monthly.
-
Subcutaneous (SC) injections for Herceptin and similar drugs exist (e.g., Phesgo – combo of trastuzumab + pertuzumab).
Injection Site Effects:
-
Local irritation: swelling, pain, redness
-
Deep tissue necrosis (rare but possible with IM injections)
-
Lipodystrophy with repeated injections
-
Fibrosis or scar tissue buildup in injection zones
Liver & Kidney Considerations
Liver:
-
Primary site of drug metabolism
-
Many breast cancer drugs increase ALT/AST (transaminases), sometimes causing hepatotoxicity
-
Monitor for steatosis, fibrosis, or drug-induced hepatitis
Kidney:
-
Less involved in metabolism but critical in excretion (especially for small-molecule inhibitors)
-
CDK4/6 inhibitors and some HER2 drugs can cause proteinuria or electrolyte imbalance
Labs to Monitor:
-
LFTs (Liver Function Tests)
-
Creatinine, BUN
-
Electrolytes
-
Cardiac echo (for Herceptin)
Dietary Recommendations for Patients on Endocrine or Targeted Therapy
General Guidelines:
-
Anti-inflammatory focus: leafy greens, berries, turmeric, ginger, green tea
-
Phytoestrogens (e.g., flaxseed, soy) – safe in moderation for ER+ patients
-
Cruciferous vegetables: broccoli, kale, cauliflower – aid detoxification
-
Liver support: dandelion root tea, milk thistle (only with medical approval)
-
Bone health: calcium + vitamin D, magnesium, boron
-
Limit alcohol, processed sugar, and saturated fats
Avoid:
-
Grapefruit (CYP450 interaction with many drugs)
-
High-dose supplements without medical clearance
-
Fasting or detox diets during active treatment (unless under supervision)
Holistic & Lifestyle Support
Domain | Recommendation |
---|---|
Sleep | Minimum 7–8 hours, melatonin if needed (low dose) |
Exercise | Gentle weight-bearing + cardio for bone & mood |
Emotional | Support groups, therapy, journaling, spiritual grounding |
Supplements | Vitamin D, B-complex, omega-3s (check drug interactions) |
References (Scientific & Clinical)
-
National Cancer Institute (NCI):
-
Breast Cancer Treatment (PDQ®)–Health Professional Version.
-
-
American Cancer Society:
-
Hormone Therapy for Breast Cancer
-
https://www.cancer.org/cancer/breast-cancer/treatment/hormone-therapy.html
-
-
ASCO (American Society of Clinical Oncology):
-
Breast Cancer Treatment Guidelines
-
https://www.asco.org/research-guidelines/quality-guidelines/guidelines
-
-
European Society for Medical Oncology (ESMO):
-
Clinical Practice Guidelines: Early and Metastatic Breast Cancer
-
-
FDA Drug Database:
-
Drug labels and black box warnings for Tamoxifen, Herceptin, Faslodex, and others.
-
-
Journal of Clinical Oncology, 2022-2024 Issues
-
Recent studies on CDK4/6 inhibitors, HER2-targeted therapy, and long-term organ toxicity.
-
-
National Comprehensive Cancer Network (NCCN):
-
Breast Cancer Guidelines, Patient Versions
-
-
Memorial Sloan Kettering Cancer Center (MSKCC):
-
Nutritional & Integrative Care in Breast Cancer
-
-
PubMed/NIH Library (key peer-reviewed studies):
-
Studies on Fulvestrant, Trastuzumab, Aromatase Inhibitors
-
Glossary of Abbreviations
Abbreviation | Full Term | Explanation |
---|---|---|
ER+ | Estrogen Receptor Positive | Tumor grows in response to estrogen |
PR+ | Progesterone Receptor Positive | Tumor grows in response to progesterone |
HER2 | Human Epidermal Growth Factor Receptor 2 | Protein promoting cancer cell growth |
SERM | Selective Estrogen Receptor Modulator | Blocks estrogen receptors (e.g., Tamoxifen) |
SERD | Selective Estrogen Receptor Degrader | Degrades estrogen receptors (e.g., Fulvestrant) |
AI | Aromatase Inhibitor | Prevents estrogen production (e.g., Letrozole) |
CDK4/6 | Cyclin-Dependent Kinase 4/6 | Enzyme targets for cell cycle regulation |
LFTs | Liver Function Tests | Measures liver health via enzymes |
BUN | Blood Urea Nitrogen | Kidney function test |
ALT/AST | Alanine/ Aspartate Transaminase | Liver enzymes tested in liver panels |
IM | Intramuscular | Injection into muscle |
SC | Subcutaneous | Injection under the skin |
TNBC | Triple-Negative Breast Cancer | Lacks ER, PR, and HER2 receptors |
CYP450 | Cytochrome P450 Enzyme System | Liver enzyme family responsible for drug metabolism |